Improvement of early 18F-FDG PET interpretation in diffuse large B-Cell lymphoma: Importance of the reference background

Journal of Nuclear Medicine

Volumn 51, Issue 12, 2010, Pages 1857-1862

  Itti, Emmanuel ^a,b   Juweid, Malik E ^c   Haioun, Corinne ^a   Yeddes, Imene ^a   Hamza Maaloul, Fatma ^a   El Bez, Intidhar ^a   Evangelista, Eva ^a   Lin, Chieh ^a,d   Dupuis, Jehan ^a   Meignan, Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c UNIVERSITY OF IOWA   (United States)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Lymphoma; PET; Prognosis; Response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; LARGE CELL LYMPHOMA; LIVER; MAJOR CLINICAL STUDY; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STANDARD; TREATMENT RESPONSE; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METHODOLOGY; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; SCINTISCANNING; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; LIVER; LYMPHOMA, LARGE B-CELL, DIFFUSE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 78651275586     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.080556     Document Type: Article

References (23)

1. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523.
2. 18F]fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381.
3. 18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746-3752.
4. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
5. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50(suppl 1):21S-30S.
6. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578.
7. ClinicalTrials.gov Web site. A Study of Two Associations of Rituximab and Chemotherapy, with a PET-Driven Strategy, in Lymphoma (LNH2007-3B). Available at: http://clinicaltrials.gov/ct2/show/NCT00498043. Accessed October 4, 2010.
8. Casasnovas O, Morschhauser F. The LNH07-3B study. 2nd International Workshop on Interim PET in Lymphoma. Available at: http://eitti.free.fr. Accessed October 14, 2010.
9. 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-1632.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
11. Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol. 2009;27:2739-2741.
12. ClinicalTrials.gov Web site. Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (PETAL). Available at: http://clinicaltrials.gov/ct2/show/NCT00554164. Accessed October 4, 2010.
13. Hüttmann A, Müller S, Bockisch A, et al. Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas (PETAL trial): correlation between clinical variables and PET parameters [abstract]. Blood. 2009;114:2695.
14. Robinson PJ. The effects of cancer chemotherapy on liver imaging. Eur Radiol. 2009;19:1752-1762.
15. Kanstrup IL, Klausen TL, Bojsen-Moller J, Magnusson P, Zerahn B. Variability and reproducibility of hepatic FDG uptake measured as SUVas well as tissue-to-blood background ratio using positron emission tomography in healthy humans. Clin Physiol Funct Imaging. 2009;29:108-113.
16. 18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30:682-688.
17. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007;48(suppl 1):19S-27S.
18. 18F-FDG uptake in tumor lesions after chemotherapy. J Nucl Med. 2007;48:390-397.
19. 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527-533.
20. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma: comparison with CT. Leuk Lymphoma. 2000;39:543-553.
21. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50:1257-1260.
22. Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775-777.
23. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824-1833.